Integra LifeSciences (IART) Tops Q4 EPS by 8c, Beats on Revenues; Offers FY18 EPS Guidance In-Line with Estimates

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.64, $0.08 better than the analyst estimate of $0.56. Revenue for the quarter came in at $368.6 million versus the consensus estimate of $356.41 million.

Highlights:

• The Company completed the acquisition of Codman Neurosurgery, the largest in its history, on October 2, 2017;
• Reported revenue for the full-year 2017 was $1,188.2 million, an increase of 19.8%, or $196.2 million over the prior year; acquisitions contributed $162.1 million to the full year, while organic sales were higher by 4.6% over the prior year;
• Fourth quarter revenue was $368.6 million, an increase of 44.2%, or $112.9 million over the prior year quarter; acquisitions contributed $103.3 million to the fourth quarter, while organic sales were higher by 5.8% over the prior year quarter;
• Fourth quarter GAAP earnings per diluted share amounted to $0.56, a 60% increase over the prior year period, and includes a net tax benefit of $37.9 million, or $0.47 per diluted share, associated with the U.S. Tax Cuts and Jobs Act;
• Fourth quarter adjusted earnings per diluted share amounted to $0.64, a 23% increase over the prior year period;
• Full-year 2017 GAAP earnings per diluted share amounted to $0.82, a 12.8% decrease over the prior year; Full-year adjusted earnings per diluted share amounted to $1.94, a 10.2% increase over the prior year, which represents the fourth consecutive year of double-digit adjusted earnings per diluted share growth; and
• The Company now expects to be at the high-end of its previously provided full-year 2018 revenue guidance range of $1.46 billion to $1.48 billion, largely due to favorable foreign currency exchange rates. The Company expects full-year GAAP earnings per diluted share to be in a range of $0.60 to $0.70, and also expects full-year adjusted earnings per diluted share to be at the high-end of its previously provided range of $2.25 to $2.35, due to a lower expected tax rate associated with the U.S. Tax Cuts and Jobs Act.

"Given our strong close to the year, the momentum in our businesses, and the benefit of a lower tax rate, we remain confident that we will deliver 5% organic growth and adjusted earnings per share at the high-end of our range," said Glenn Coleman, Chief Financial Officer. "Consistent with previous guidance, we expect first quarter organic growth to be in the low single-digits as we work through the sales channel integration in both of our segments, which we believe will result in higher organic growth in the second half of 2018."

GUIDANCE:

Integra LifeSciences sees FY2018 EPS of $2.25-$2.35, versus the consensus of $2.30.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Nike names former Pfizer CFO David Denton as new finance chief